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Abstract
Background: Obesity, inflammation and alterations in matrix metalloproteinase-9
(MMP-9) and nitric oxide (NO) levels are involved in the development of polycystic ovary
syndrome (PCOS).
Objective: To investigate the relationship of MMP-9, NO and interleukin-10 (IL-10) with
the increase in body mass index (BMI) in women with PCOS.
Materials and Methods: Sixty two infertile PCOS women were included in the study.
Serum levels of NO, IL-10 and MMP-9 were assessed in the women with increase in
BMI.
Results: MMP-9 was significantly increased (p = 0.029) and IL-10 (p = 0.015) was
significantly reduced in obese PCOS subjects compared to thosewith lesser BMI. MMP-
9 levels positively correlated with the duration of infertility (r = 0.253, p = 0.047) and
negatively correlated with NO levels (r = - 0.259, p = 0.042). A significant negative
correlation between the interleukin-10 levels and the BMI (r = - 0.272, p = 0.033) was
also found in the PCOS subjects.
Conclusion: MMP-9 levels are increased in obese PCOS women and it is associated
with NO levels and the duration of infertility.
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1. Introduction
Polycystic ovary syndrome (PCOS) is a common
multifaceted hormonal disorder that affects
almost 5-10 % of women in the reproductive
age group (1). Reproductive abnormalities like
ovulatory dysfunction, infertility and features
of hyperandrogenism are the most common
manifestations. PCOS subjects are at an increased
risk of developing metabolic complications like
diabetes mellitus, and cardiovascular disease (2).
Several investigators have emphasized the
role of obesity as a contributing factor in
the pathogenesis of PCOS. Body mass index
(BMI) was found to be increased in 50-60%
of women with PCOS (3). Obesity is known to
be associated with infertility and the influence
of obesity on the exacerbation of clinical
features and hormonal disturbances of PCOS
has been revealed the past by many earlier
studies (4). Healthy dietary habits and weight
reduction have shown a beneficial impact
on the metabolic state, hyperandrogenemia,
ovulatory function and pregnancy rates in PCOS
suggesting the importance of maintaining a
healthy body weight for women with PCOS
(5).
Matrix metalloproteinase-9 (MMP-9) is a
zinc-dependent enzyme involved in the tissue
remodeling of the ovary and uterus, which is
responsible for growth of the follicle, formation
of corpus luteum and blastocyst implantation (6).
Elevated MMP-9 expression has been reported
to be involved in trophoblast invasion during
pregnancy (7). Previous studies have hypothesized
that increased MMP-9 levels might be related
to menstrual irregularities and increased risk
of cardiovascular disease in PCOS patients (6,
8).
Nitric oxide (NO) plays a crucial role in pregnancy
and it promotes embryonic development,
maintains the fetoplacental unit and sustains
pregnancy (9). Reduced NO levels in women with
PCOS were found to be related with spontaneous
pregnancy (10).
Inflammation is usually associated with PCOS,
which influences ovarian folliculogenesis, altered
steroidogenesis in ovary and hyperinsulinemia
in these women (11). Interleukin-10 (IL-10),
an anti-inflammatory cytokine regulates the
action of pro-inflammatory cytokines during
inflammation. IL-10 gene polymorphism has been
reported in PCOS and reduced IL-10 levels have
been documented in women with PCOS (11,
12).
Since obesity and alteration in inflammation and
matrixmetalloproteinases are important underlying
factors associated with the metabolic, hormonal
and reproductive abnormalities in PCOS (13-15), this
study was intended to determine the influence of
increase in body mass index onMMP-9, nitric oxide
and interleukin-10 in PCOS.
2. Materials and Methods
2.1. Subjects
The present study was a cross sectional study
conducted in the department of Biochemistry
and Obstetrics & Gynaecology, Jawaharlal
Institute of Post Graduate Medical Education
and Research, Puducherry, India from December
2014 to July 2016. Sixty two PCOS subjects
in the age group of 20-35 yr, were enrolled
in the study. The diagnosis of PCOS in the
participants was made based on the revised
Rotterdam criteria 2003 (16). The subjects with
medical comorbidities, fallopian tube disorders,
ovarian failure, endometriosis and those who
were using metformin were excluded from the
study.
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2.2. Clinical evaluation
The study subjects were evaluated by a detailed
clinical history, treatment history and physical
examination.
2.3. Sample collection
Venous blood samples of 5 ml were collected
from the participants. Serum was separated and
stored at - 80°C and used to assess the NO, IL-10
and MMP-9 levels.
2.4. Biochemical analysis
Colorimetric method (Oxford Biomedical
Research, USA) was used to analyze serum
NO levels. Serum IL-10 (Diaclone, France) and
MMP-9 (Raybiotech, Mexico) were analyzed by
ELISA.
2.5. Ethical consideration
The present study was approved by the
Institution ethics Committee for human studies
(Ref: JIP/IEC/2014/8/367). Written informed consent
was obtained from all the subjects prior to the
study.
2.6. Statistical analysis
All continuous data are displayed as mean
± SD. One way ANOVA was used to compare
the parameters between the three groups of
PCOS. Correlations were determined using
Pearson correlation analysis. A p-value < 0.05
was considered as significant. Statistical analysis
was done using IBM SPSS Statistics 16 (IBM
Corporation, Somers, NY).
3. Results
The differences in age, clinical characteristics
and biochemical parameters among the PCOS
subjects, grouped on the basis of their BMI, are
shown in Table I. PCOS subjects with BMI > 30
kg/m2 had significantly higher levels of MMP-9 (p
= 0.029) compared to those with BMI between 25
and 28 kg/m2. IL-10 was found to be significantly
lower in PCOS subjects with BMI between 25 and
28 kg/m2 (p = 0.002), BMI between 28 and 30
kg/m2 (p = 0.002) and BMI > 30 kg/m2 (p = 0.015)
compared to those with a normal BMI < 25 kg/m2.
There was no significant difference in the no levels,
age and duration of infertility among the PCOS
subjects.
Table II shows the correlation of MMP-9 with
age, BMI and biochemical parameters like IL-10 and
NO in the PCOS subjects. MMP-9 was positively
correlated with the duration of infertility (r = 0.253,
p = 0.047) and negatively correlated with NO (r = -
0.259, p = 0.042). IL-10 was negatively associated
with BMI (r = -0.272, p = 0.033) and the duration
of infertility was positively associated with age (r =
0.374, p = 0.003) in PCOS subjects.
Table I. Mean and SD of age, clinical characteristics and biochemical parameters in PCOS subjects (n = 62) with increase in BMI
Parameters PCOS subjects (n = 62)
BMI < 25 kg/m2 (n = 14) BMI 25-28 kg/m2 (n = 32) BMI 28-30 kg/m2 (n = 9) BMI > 30 kg/m2 (n = 7)
Age 24.8 ± 2.5 25.4 ± 2.8 26.1± 3.5 24.7 ± 2.3
Duration of infertility 2.5 ± 0.73 2.54 ± 0.62 3.05 ± 1.28 2.85 ± 0.69
MMP-9 2995 ± 561 2691 ± 692 3171 ± 673 3319 ± 766*
Interleukin-10 10.96 ± 8.11 5.42 ± 4.25* 3.68 ± 3.0* 4.89 ± 3.95*
Nitric oxide 20.68 ± 8.36 18.53 ± 5.96 19.2 ± 5.35 18.2 ± 4.43
*P < 0.01 compared to PCOS subjects with BMI < 25 kg/m2, **p < 0.05 compared to PCOS subjects with BMI 25 - 28 kg/m2
PCOS subjects with BMI > 30 kg/m2 had significantly higher levels of MMP-9 (p < 0.05) compared to those with BMI between
25 and 28 kg/m2. Interleukin-10 was found to be significantly lower in PCOS subjects with BMI between 25 and 28 kg/m2 (p
< 0.01), BMI between 25 and 28 kg/m2 (p < 0.01) and BMI > 30 kg/m2 (p < 0.01) compared to those with a normal BMI < 25
kg/m2. There was no significant difference in the nitric oxide levels, age and duration of infertility among the PCOS subjects.
Statistical test used: One-way ANOVA was used to compare the parameters between the three groups of PCOS
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Nitric oxide -0.259 0.042
Interleukin-10 0.285 0.025
Duration of infertility 0.253 0.047
MMP-9 was positively correlated with the duration of infertility (r = 0.253, p = 0.047) and negatively correlated with nitric oxide
(r = - 0.259, p = 0.042) in PCOS.
Statistical test used: Pearson correlation analysis
4. Discussion
In the present study, MMP-9 was increased and
IL-10 was reduced in PCOS women with increase in
BMI. MMP-9 was associated with NO and duration
of infertility in PCOS.
Several factors such as inflammation, endothelial
dysfunction and altered ovarian remodelling are
known to play a role in the pathogenesis of PCOS
and its complications including infertility (17-19).
Obesity has got a major influence on the clinical
outcome of PCOS as evident by the presence of
hyperandrogenism, insulin resistance, decreased
ovulation as well as lower pregnancy rates in PCOS
women with obesity in comparison with non-obese
PCOS women (20).
MMP-9, a matrix metalloproteinase produced
by the ovary is involved in various phases of
female reproduction. High MMP-9 levels in PCOS
adversely affects ovulation and fertility, as it alters
the extracellular matrix remodelling thus causing
aberrant follicular atresia and increased ovarian
stromal tissue (21). MMP-9 is reported to be strongly
associated with obesity and furthermore the
presence of a high BMI has also been hypothesized
to promote poor ovulation and thereby lesser
chances of pregnancy (22). In our study, we
observed that MMP-9 levels were higher in infertile
women with PCOS having a BMI > 30 kg/m2
compared to those with BMI between 25 and 28
kg/m2. These findings were supported by previous
studies that have reported high MMP-9 in obese
subjects (22, 23). As body weight increases, fat
cells are enlarged and adipose tissue is expanded
and differentiated. During differentiation of adipose
tissue, the activity of MMP-9 is induced resulting in
remodeling of stromal matrix (24).
NO has a pivotal role in endothelial function by
which it regulates the uterine blood flow, relaxes
the uterine myometrium and reduces the feto-
placental vascular resistance during pregnancy
(25) NO levels are found to be reduced both
in obesity and PCOS subjects which might be
associated with adverse pregnancy outcome (26,
27). In our study, we observed a reduction in the
nitric oxide levels as BMI increased however, it was
not statistically significant. Decreased serum NO
levels in PCOS have been attributed to elevated
asymmetrical dimethyl arginine (ADMA) in PCOS
subjects associated with hyperandrogenemia and
insulin resistance (28, 29).
Extensive studies have documented the role of
inflammation in PCOS and reported an imbalance
in the levels of pro and anti-inflammatory
cytokines in these subjects (11). Obesity and
inflammation are known to occur concurrently
(30). The presence of hyperandrogenemia in
PCOS stimulates adipocyte hypertrophy and
hypoperfusion, release of inflammatory mediators
and development of chronic inflammation,
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consequently resulting in insulin resistance and
cardiovascular complications (28). Low levels of
IL-10 were observed in PCOS and it was found
to affect the pregnancy rates and outcomes (31).
Our data demonstrated a significant reduction
in the serum IL-10 levels of infertile women with
PCOS who had a BMI in the range of 25-28
kg/m2, 28-30 kg/m2, and > 28 kg/m2 compared
to those who had a normal BMI. Also IL-10 was
negatively associated with BMI suggesting that
as BMI increases, IL-10 reduces in PCOS subjects.
These findings were in agreement with previous
reports that demonstrate reduction in IL-10 levels
in obesity and PCOS (31, 32). Since weight gain
is associated with inflammation (33), there is
reduction of anti-inflammatory cytokines like IL-10.
In the present study, MMP-9 levels negatively
correlated with NO levels and positively correlated
with the duration of infertility in PCOS subjects.
These findings suggest that as the duration of
infertility increases, the MMP-9 level increases
which in turn reduces NO levels leading to the
complications of PCOS.
In the present study we have investigated
whether thesemarkers are altered in PCOSwomen
with increase in body weight / BMI. Alteration in
these markers can lead to reduction in ovulation.
Based on the findings of our study we suggest
that weight reduction in PCOS can reduce MMP-
9 and increase IL-10, which may improve ovulation
in these subjects. The main limitations of the
study are the small sample size and non-inclusion
of healthy control groups. Moreover we did not
estimate other inflammatory cytokines due to
financial constraints.
5. Conclusion
The present study concludes that as BMI
increases MMP-9 is increased and IL-10 is reduced
in PCOS subjects. The association of MMP-9 with
NO and duration of infertility indicates that high
MMP-9 levels may cause endothelial dysfunction
which might be responsible for complications in
PCOS subjects with obesity. Further studies are
required to investigate whether weight reduction
reduces MMP-9 levels and the complications of
PCOS in obese subjects.
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